AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
– Company presentation scheduled for January 11, 2018 –
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, Calif., on January 11, 2018 at 7:30 a.m. Pacific Time.
A live audio webcast of the presentation will be available in the "Investors" section of Achaogen’s website, www.achaogen.com. A replay of the presentation will be archived on the website for 30 days following the conference.
About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. The Food and Drug Administration has granted plazomicin Breakthrough Therapy designation for the treatment of bloodstream infections caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options. The Company's second product candidate is C-Scape, an orally-administered product candidate for the treatment of serious bacterial infections due to ESBL-producing Enterobacteriaceae. Achaogen's plazomicin program has been funded, and its C-Scape program is funded, in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA). Achaogen has other programs in early and late preclinical stages of development focused on other MDR gram-negative infections and additional disease areas. All product candidates, including plazomicin, are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.
Source: Achaogen, Inc. (NASDAQ:AKAO)
Investor and Media Contact
David Arrington
Vice President, Investor Relations and Corporate Communications
650.440.5856
[email protected]
